权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Serum anti-phospholipid antibodies in patients with multiple sclerosis

多发性硬化症患者血清抗磷脂抗体

基本信息

批准号：
05670566
负责人：
YAMAMOTO Teiji
金额：
$ 1.28万
依托单位：
Fukushima Medical College
依托单位国家：
日本
项目类别：
Grant-in-Aid for General Scientific Research (C)
财政年份：
1993
资助国家：
日本
起止时间：
1993 至 1994
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-05670566/
关键词：
multiple sclerosis anti-phospholipid antibodies 2-glycoprotein I

项目摘要

We have measured serum antiphospholipid antibodies (aPL) in patients with multiple sclerosis (MS) using enzyme linked immunosorbent assey and examined the correlations between these antibodies and MS.This study included thirty-two patients with clinically definite MS,thirteen patients with other autoimmune neurological disease excluding collagen vascular diseases (disease control.A) , eight patients with collagen vascular diseases (disease control.B) and twenty-six healthy persons (normal control) . In MS group IgG antibody against cardiolipin (CL) was detected in 3 (9%) ; anti-CL antibody showed cofactor (2-glycoprotein I) dependency in 2 but one was cofactor independent. IgM antibody was elevated in 14 of 32 patients (449%) with MS,but cofactor dependency was not determined. However, this was significantly higer in frequecy than that of the disease control A (P<0.01) and normal control (P<0.01) . Each anti-CL IgG antibody purified from four patients had differed reactivities against DNA.In addition, the APLA positive group in MS possessed at higer rate of other autoantibodies such as antinuclear antibody than the negative group. However, clinically two groups of MS were indistinguishable. The higher incidence of APLA imply that a broad spectrum of autoantibodies might be produced in MS ; some antibodies presumably related directly to MS pathogenesis are yet to be identified but APLA might be one of those antibodies which are to be tested for the capability of central inflammation and demyelination.

应用酶联免疫吸附试验检测多发性硬化(MS)患者血清抗磷脂抗体(APL)，并探讨其与MS的相关性。研究对象包括32例临床确诊的MS患者、13例除胶原血管疾病外的其他自身免疫性神经系统疾病患者(A组)、8例胶原血管病患者(B组)和26例正常人(对照组)。MS组中3例(9%)检测到抗心磷脂(CL)抗体，2例为辅因子(2-糖蛋白I)依赖性抗体，1例为非辅因子依赖性抗体。32例MS患者中有14例(449%)IgM抗体升高，但未发现辅因子依赖性。然而，这一频率显著高于疾病对照A组(P&lt；0.01)和正常对照组(P&lt；0.01)。从4例患者中提纯的抗CL-Ig G抗体对DNA具有不同的反应活性，此外，MS患者APLA阳性组中其他自身抗体如抗核抗体的发生率也高于阴性组。然而，在临床上，两组MS是无法区分的。APLA的高发病率意味着MS可能产生了广泛的自身抗体；一些可能与MS发病机制直接相关的抗体尚未确定，但APLA可能是需要检测的抗体之一，以检测其中枢炎症和脱髓鞘的能力。